The Filing Desk

Nephros vs Vivos Therapeutics

Nephros NEPH · Vivos Therapeutics VVOS · Health Care Equipment

Nephros reported revenue of $19 million in fiscal 2025, about the same as Vivos Therapeutics' $17 million in fiscal 2025. Nephros' revenue grew 32.7% in its latest year, and Vivos Therapeutics' grew 16.1%. Nephros had an operating margin of 6.1%, against -114.0% at Vivos Therapeutics.

Side by side

NephrosVivos Therapeutics
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$19M$17M
Revenue growth32.7%16.1%
Revenue growth a year, last 5 years16.9%5.8%
Gross margin61.9%60.4%
Operating margin6.1%−114.0%
Net margin6.3%−121.4%
Free cash flow—−$18M
Free cash flow margin—−100.9%
Return on capital——
Net debt to EBITDA——
Dividends and buybacks$0M$0M
Change in diluted share count3.5%104.7%
Last close$2.84$0.06
P/E at the last close15.8×—
Insider trades, last 12 monthsbought $22,075, sold $0bought $1.8 million, sold $0
Piotroski F-score—3 of 9
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
NephrosVivos Therapeutics
Operating margin
Percent of revenue
NephrosVivos Therapeutics
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
NephrosVivos Therapeutics

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Nephros and Vivos Therapeutics pages.